Transferrin-Decorated Protein-Lipid Hybrid Nanoparticle Efficiently Delivers Cisplatin and Docetaxel for Targeted Lung Cancer Treatment

References

• TorreLA, SiegelRL, JemalA. Lung cancer statistics. Adv Exp Med Biol. 2016;893:1–19.26667336
   PubMed Web of Science ®Google Scholar
• ScheffRJ, SchneiderBJ. Non-small-cell lung cancer: treatment of late stage disease: chemotherapeutics and new frontiers. Semin Intervent Radiol. 2013;30(2):191–198. doi:10.1055/s-0033-134296124436536
   PubMed Web of Science ®Google Scholar
• ChenL, KimJS, San AntonioB, ZhuYE, MitchellL, JohnW. Safety outcomes in advanced non-small-cell lung cancer patients treated with first-line platinum-based regimens in the United States. J Thorac Dis. 2019;11(11):4474–4483. doi:10.21037/jtd.2019.11.1131903235
   PubMed Web of Science ®Google Scholar
• AzzoliCG, BakerSJr, TeminS, et al., American Society of Clinical Oncology. American society of clinical oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2009;27(36):6251–6266. doi:10.1200/JCO.2009.23.562219917871
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-Analyses Collaborative Group. Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials. J Clin Oncol. 2008;26(28):4617–4625. doi:10.1200/JCO.2008.17.716218678835
   PubMed Web of Science ®Google Scholar
• SchillerJH, HarringtonD, BelaniCP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med. 2002;346(2):92–98.11784875
   PubMed Web of Science ®Google Scholar
• KellyK, CrowleyJ, BunnPAJr, et al. Randomized Phase III trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non–small-cell lung cancer: a Southwest Oncology Group trial. J Clin Oncol. 2001;19(13):3210–3218. doi:10.1200/JCO.2001.19.13.321011432888
   PubMed Web of Science ®Google Scholar
• SocinskiMA, BondarenkoI, KarasevaNA, et al. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. J Clin Oncol. 2012;30(17):2055–2062. doi:10.1200/JCO.2011.39.584822547591
   PubMed Web of Science ®Google Scholar
• Al-AttarT, MadihallySV. Recent advances in the combination delivery of drug for leukemia and other cancers. Expert Opin Drug Deliv. 2020;22:1–11.
   Google Scholar
• LiuTI, LuTY, ChangSH, ShenMY, ChiuHC. Dual stimuli-guided lipid-based delivery system of cancer combination therapy. J Control Release. 2020;318:16–24. doi:10.1016/j.jconrel.2019.12.00231809761
   PubMed Web of Science ®Google Scholar
• LiS, WangL, LiN, LiuY, SuH. Combination lung cancer chemotherapy: design of a pH-sensitive transferrin-PEG-Hz-lipid conjugate for the co-delivery of docetaxel and baicalin. Biomed Pharmacother. 2017;95:548–555. doi:10.1016/j.biopha.2017.08.09028869892
   PubMed Web of Science ®Google Scholar
• LiuB, HanL, LiuJ, HanS, ChenZ, JiangL. Co-delivery of paclitaxel and TOS-cisplatin via TAT-targeted solid lipid nanoparticles with synergistic antitumor activity against cervical cancer. Int J Nanomedicine. 2017;31(12):955–968. doi:10.2147/IJN.S115136
   Web of Science ®Google Scholar
• GaberM, MedhatW, HanyM, SaherN, FangJY, ElzoghbyA. Protein-lipid nanohybrids as emerging platforms for drug and gene delivery: challenges and outcomes. J Control Release. 2017;28(254):75–91. doi:10.1016/j.jconrel.2017.03.392
   Web of Science ®Google Scholar
• MüllerRH, MäderK, GohlaS. Solid lipid nanoparticles (SLN) for controlled drug delivery - a review of the state of the art. Eur J Pharm Biopharm. 2000;50(1):161–177. doi:10.1016/S0939-6411(00)00087-410840199
   PubMed Web of Science ®Google Scholar
• JungSH, KimSK, JungSH, et al. Increased stability in plasma and enhanced cellular uptake of thermally denatured albumin-coated liposomes. Colloids Surf B Biointerfaces. 2010;76(2):434–440. doi:10.1016/j.colsurfb.2009.12.00220036109
   PubMed Web of Science ®Google Scholar
• XuY, JinX, PingQ, et al. A novel lipoprotein-mimic nanocarrier composed of the modified protein and lipid for tumor cell targeting delivery. J Control Release. 2010;146(3):299–308. doi:10.1016/j.jconrel.2010.05.02220580913
   PubMed Web of Science ®Google Scholar
• PandeyV, GajbhiyeKR, SoniV. Lactoferrin-appended solid lipid nanoparticles of paclitaxel for effective management of bronchogenic carcinoma. Drug Deliv. 2015;22(2):199–205. doi:10.3109/10717544.2013.87710024467582
   PubMed Web of Science ®Google Scholar
• KuoYC, ChengSJ. Brain targeted delivery of carmustine using solid lipid nanoparticles modified with tamoxifen and lactoferrin for antitumor proliferation. Int J Pharm. 2016;499(1–2):10–19. doi:10.1016/j.ijpharm.2015.12.05426721730
   PubMed Web of Science ®Google Scholar
• XuG, ChenY, ShanR, WuX, ChenL. Transferrin and tocopheryl-polyethylene glycol-succinate dual ligands decorated, cisplatin loaded nano-sized system for the treatment of lung cancer. Biomed Pharmacother. 2018;99:354–362. doi:10.1016/j.biopha.2018.01.06229358128
   PubMed Web of Science ®Google Scholar
• TanS, WangG. Lung cancer targeted therapy: folate and transferrin dual targeted, glutathione responsive nanocarriers for the delivery of cisplatin. Biomed Pharmacother. 2018;102:55–63. doi:10.1016/j.biopha.2018.03.04629549729
   PubMed Web of Science ®Google Scholar
• ZhangB, ZhangY, YuD. Lung cancer gene therapy: transferrin and hyaluronic acid dual ligand-decorated novel lipid carriers for targeted gene delivery. Oncol Rep. 2017;37(2):937–944. doi:10.3892/or.2016.529827959442
   PubMed Web of Science ®Google Scholar
• ZhangQ, TianX, CaoX. Transferrin-functionalised microemulsion co-delivery of β-elemene and celastrol for enhanced anti-lung cancer treatment and reduced systemic toxicity. Drug Deliv Transl Res. 2019;9(3):667–678. doi:10.1007/s13346-019-00623-430798476
   PubMed Web of Science ®Google Scholar
• YueY, ZhaoD, YinQ. Hyaluronic acid modified nanostructured lipid carriers for transdermal bupivacaine delivery: in vitro and in vivo anesthesia evaluation. Biomed Pharmacother. 2018;98:813–820. doi:10.1016/j.biopha.2017.12.10329571251
   PubMed Web of Science ®Google Scholar
• LopalcoA, CutrignelliA, DenoraN, LopedotaA, FrancoM, LaquintanaV. Transferrin functionalized liposomes loading dopamine HCL: development and permeability studies across an in vitro model of human blood-brain barrier. Nanomaterials (Basel). 2018;8(3):178. doi:10.3390/nano8030178
   Google Scholar
• JuangV, ChangCH, WangCS, WangHE, LoYL. pH-responsive PEG-shedding and targeting peptide-modified nanoparticles for dual-delivery of irinotecan and microRNA to enhance tumor-specific therapy. Small. 2019;15(49):e1903296. doi:10.1002/smll.20190329631709707
   PubMed Web of Science ®Google Scholar
• GuoS, WangY, MiaoL, et al. Lipid-coated cisplatin nanoparticles induce neighboring effect and exhibit enhanced anticancer efficacy. ACS Nano. 2013;7(11):9896–9904. doi:10.1021/nn403606m24083505
   PubMed Web of Science ®Google Scholar
• GuanQ, SunD, ZhangG, et al. Docetaxel-loaded self-assembly stearic acid-modified bletilla striata polysaccharide micelles and their anticancer effect: preparation, characterization, cellular uptake and in vitro evaluation. Molecules. 2016;21(12):1641. doi:10.3390/molecules21121641
   PubMed Web of Science ®Google Scholar
• HanS, SunR, SuH, et al. Delivery of docetaxel using pH-sensitive liposomes based on D-α-tocopheryl poly(2-ethyl-2-oxazoline) succinate: comparison with PEGylated liposomes. Asian J Pharm Sci. 2019;14(4):391–404. doi:10.1016/j.ajps.2018.07.00532104468
   PubMed Web of Science ®Google Scholar
• LiM, TangZ, LvS, et al. Cisplatin crosslinked pH-sensitive nanoparticles for efficient delivery of doxorubicin. Biomaterials. 2014;35(12):3851–3864. doi:10.1016/j.biomaterials.2014.01.01824495487
   PubMed Web of Science ®Google Scholar
• GuoS, ZhangY, WuZ, et al. Synergistic combination therapy of lung cancer: cetuximab functionalized nanostructured lipid carriers for the co-delivery of paclitaxel and 5-demethylnobiletin. Biomed Pharmacother. 2019;118:109225. doi:10.1016/j.biopha.2019.10922531325705
   PubMed Web of Science ®Google Scholar
• HeYC, HeL, KhoshabaR, et al. Curcumin nicotinate selectively induces cancer cell apoptosis and cycle arrest through a P53-mediated mechanism. Molecules. 2019;24(22):4179. doi:10.3390/molecules24224179
   PubMed Web of Science ®Google Scholar
• TanKT, LiS, LiYR, ChengSL, LinSH, TungYT. Synergistic anticancer effect of a combination of paclitaxel and 5-demethylnobiletin against lung cancer cell line in vitro and in vivo. Appl Biochem Biotechnol. 2019;187(4):1328–1343. doi:10.1007/s12010-018-2869-130229430
   PubMed Web of Science ®Google Scholar
• WangH, ZhangF, WenH, et al. Tumor- and mitochondria-targeted nanoparticles eradicate drug resistant lung cancer through mitochondrial pathway of apoptosis. J Nanobiotechnology. 2020;18(1):8. doi:10.1186/s12951-019-0562-331918714
   PubMed Web of Science ®Google Scholar
• XieF, DingRL, WfH, et al. In vivo antitumor effect of endostatin-loaded chitosan nanoparticles combined with paclitaxel on Lewis lung carcinoma. Drug Deliv. 2017;24(1):1410–1418. doi:10.1080/10717544.2017.137893828933203
   PubMed Web of Science ®Google Scholar
• LiuH, ShenM, ZhaoD, et al. The effect of triptolide-loaded exosomes on the proliferation and apoptosis of human ovarian cancer SKOV3 cells. Biomed Res Int. 2019;2019:2595801.31240207
   PubMed Web of Science ®Google Scholar
• ZhouJ, LiM, LimWQ, et al. A transferrin-conjugated hollow nanoplatform for redox-controlled and targeted chemotherapy of tumor with reduced inflammatory reactions. Theranostics. 2018;8(2):518–532. doi:10.7150/thno.2119429290824
   PubMed Web of Science ®Google Scholar
• DongX, ShuX, WangY, et al. Synthesis, characterization and in vitro release performance of the pegylated valnemulin prodrug. J Vet Med Sci. 2018;80(1):173–180. doi:10.1292/jvms.17-043429187697
   PubMed Web of Science ®Google Scholar
• PangJ, XingH, SunY, FengS, WangS. Non-small cell lung cancer combination therapy: hyaluronic acid modified, epidermal growth factor receptor targeted, pH sensitive lipid-polymer hybrid nanoparticles for the delivery of erlotinib plus bevacizumab. Biomed Pharmacother. 2020;125:109861. doi:10.1016/j.biopha.2020.10986132070872
   PubMed Web of Science ®Google Scholar
• ZhongY, ZhangJ, ChengR, et al. Reversibly crosslinked hyaluronic acid nanoparticles for active targeting and intelligent delivery of doxorubicin to drug resistant CD44+ human breast tumor xenografts. J Control Release. 2015;205:144–154. doi:10.1016/j.jconrel.2015.01.01225596560
   PubMed Web of Science ®Google Scholar
• ChouTC, TalalayP. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci. 1983;4:450–454. doi:10.1016/0165-6147(83)90490-X
   Web of Science ®Google Scholar
• NanY. Lung carcinoma therapy using epidermal growth factor receptor-targeted lipid polymeric nanoparticles co-loaded with cisplatin and doxorubicin. Oncol Rep. 2019;42(5):2087–2096.31545462
   PubMed Web of Science ®Google Scholar
• WangJ, SuG, YinX, et al. Non-small cell lung cancer-targeted, redox-sensitive lipid-polymer hybrid nanoparticles for the delivery of a second-generation irreversible epidermal growth factor inhibitor-afatinib: in vitro and in vivo evaluation. Biomed Pharmacother. 2019;120:109493. doi:10.1016/j.biopha.2019.10949331586902
   PubMed Web of Science ®Google Scholar
• ZhengG, ZhengM, YangB, FuH, LiY. Improving breast cancer therapy using doxorubicin loaded solid lipid nanoparticles: synthesis of a novel arginine-glycine-aspartic tripeptide conjugated, pH sensitive lipid and evaluation of the nanomedicine in vitro and in vivo. Biomed Pharmacother. 2019;116:109006. doi:10.1016/j.biopha.2019.10900631152925
   PubMed Web of Science ®Google Scholar